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Abstract
Background: Human chronic liver diseases (CLDs) with different aetiologies rely on chronic
activation of wound healing that represents the driving force for fibrogenesis progression
(throughout defined patterns of fibrosis) to the end stage of cirrhosis and liver failure.
Issues: Fibrogenesis progression has a major worldwide clinical impact due to the high number of
patients affected by CLDs, increasing mortality rate, incidence of hepatocellular carcinoma and
shortage of organ donors for liver transplantation.
Basic science advances: Liver fibrogenesis is sustained by a heterogeneous population of
profibrogenic hepatic myofibroblasts (MFs), the majority being positive for α smooth muscle actin
(αSMA), that may originate from hepatic stellate cells and portal fibroblasts following a process of
activation or from bone marrow-derived cells recruited to damaged liver and, in a method still
disputed, by a process of epithelial to mesenchymal transition (EMT) involving cholangiocytes and
hepatocytes. Recent experimental and clinical data have identified, at tissue, cellular and molecular
level major profibrogenic mechanisms: (a) chronic activation of the wound-healing reaction, (b)
oxidative stress and related reactive intermediates, and (c) derangement of epithelial-mesenchymal
interactions.
Clinical care relevance: Liver fibrosis may regress following specific therapeutic interventions
able to downstage or, at least, stabilise fibrosis. In cirrhotic patients, this would lead to a reduction
of portal hypertension and of the consequent clinical complications and to an overall improvement
of liver function, thus extending the complication-free patient survival time and reducing the need
for liver transplantation.
Conclusion: Emerging mechanisms and concepts related to liver fibrogenesis may significantly
contribute to clinical management of patients affected by CLDs.
Background
Human chronic liver diseases (CLDs) are characterised by
reiteration of liver injury due to chronic infection by viral
agents (mainly hepatitis B and C viruses) or to metabolic,
toxin/drug-induced (alcohol being predominant) and
autoimmune causes. This results in the chronic activation
of the wound-healing response that represents the driving
force for progressive accumulation of extracellular matrix
(ECM) components, eventually leading to liver cirrhosis
and hepatic failure. Accordingly, cirrhosis can be defined
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regenerative nodules of parenchyma surrounded and sep-
arated by fibrotic septa, a scenario also characterised by
significant changes in hepatic angioarchitecture [1-4].
Fibrosis progression is strictly related to the underlying
cause of CLD and four distinct patterns of fibrosis progres-
sion (shown below) have been identified that are related
to the 'topographic site' of tissue injury (as previously
reported in detail [2]), the involvement of different popu-
lations of hepatic myofibroblast-like (MF) cells and the
predominant profibrogenic mechanism [2,4,5].
Bridging fibrosis
This is typically found in chronic viral hepatitis, consid-
ered as result of portal-central (vein) bridging necrosis,
resulting primarily in the formation of portal-central
fibrotic septa. Interface hepatitis, development of portal-
portal septa and early changes in vascular connections
with portal system complete this scenario.
Perisinusoidal/pericellular fibrosis
This is typically found in non-alcoholic steatohepatitis
(NASH) or associated with alcoholic aetiology (ALD);
excess deposition of ECM is primarily in the spaces of
Disse around sinusoids or groups of hepatocytes, leading
to the two scenarios of 'capillarisation of sinusoids' or
'chicken-wire pattern', respectively.
Biliary fibrosis
This is a pattern sustained by concomitant proliferation of
reactive bile ductules and periductular MFs at the interface
between portal areas and parenchyma, leading to the
characteristic development of portal-portal fibrotic septa.
Centrolobular fibrosis
This is secondary to conditions altering venous outflow,
as in chronic heart failure, characterised by the develop-
ment of central-central (vein) fibrotic septa.
Clinical problems
Fibrogenesis progression has a major clinical impact
because [2,4]: (1) millions of patients worldwide are
affected by a form of CLD, and among these 25% to 30%
are expected to develop significant fibrosis and cirrhosis;
(2) liver cirrhosis is the most common non-neoplastic
cause of death in Europe and USA among diseases inter-
esting the gastrointestinal (GI) tract, and represents the
seventh most common cause of death in western coun-
tries; (3) liver cirrhosis predisposes patients to hepatocel-
lular carcinoma (HCC) that further increases mortality
rate; (4) epidemiological analysis predict a peak for
advanced CLD in the next decade, with an increased
number of patients reaching end-stage disease and requir-
ing liver transplantation.
Relevant basic science context
Liver fibrogenesis is sustained by a heterogeneous popula-
tion of profibrogenic hepatic MFs expressing a peculiar
repertoire of antigens [5], including α smooth muscle
actin (αSMA), which is expressed by the majority, but not
all, of these cells. On the basis of tissue localisation and/
or antigen profile different populations of MFs may be
recognised: (a) activated, MF-like, hepatic stellate cells
(HSC-MFs) found primarily in or around capillarised
sinusoids of fibrotic/cirrhotic livers; (b) portal/septal MFs
(PS/MFs) found in the connective tissue around expanded
portal tracts or in the inner part of fibrotic septa; and (c)
interface MFs (IF/MFs), found at the edge between fibrotic
septa and the surrounding parenchyma.
Hepatic MFs can originate from different cellular sources:
(1) activation of hepatic stellate cells [1-6] where HSC/
MFs are likely to predominate in a pattern of 'perisinusoi-
dal/pericellular fibrosis' and contribute to 'bridging fibro-
sis'; (2) activation of portal fibroblasts (that can give
origin also to septal MFs), relevant in ischemic conditions
and in obstructive cholestatic diseases and giving origin
also to septal MFs; (3) MFs (IF/MFs and some portal MFs)
may originate from recruitment of bone marrow derived
cells [7] such as mesenchymal stem cells (MSCs) [8,9] and
circulating fibrocytes [10]; and (4) MFs, with a significant
number of cells reported to be αSMA negative, may also
originate by means of epithelial to mesenchymal transi-
tion (EMT) of hepatocytes and/or cholangiocytes [11,12],
although this possibility remains controversial.
Present knowledge on profibrogenic MFs is derived
mainly from studies performed on human or rodent HSC/
MFs [1-6,13,14]. Activation of HSCs in CLD progresses in
sequential stages of initiation and perpetuation. Initiation
is an early response stimulated by paracrine signals and
leading to a transient and potentially reversible contractile
and profibrogenic phenotype, characterised by rapid
induction of platelet-derived growth factor (PDGF)β
receptor and primed to respond to several growth factors
and mediators that will be crucial in eliciting phenotypic
responses operated by fully activated MF-like phenotype
(perpetuation), including proliferation, migration/chem-
otaxis, contractility, excess deposition and altered remod-
elling of ECM (Figure 1).
Experimental models or material: advantages and 
limitations
Major advances in our understanding of fibrogenic mech-
anisms come directly from experimental studies. Studies
on primary cultures of rat and human HSCs have dis-
sected mechanisms and signalling pathways controlling
the process of activation and related major phenotypic
responses, in a scenario [1-6] that identifies these cells as
crucial cellular crossroads in a complex sinusoidal envi-Page 2 of 6
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crine crosstalk, rapid responses to evolving ECM content,
and selective responsiveness to the metabolic needs
imposed by liver growth and repair. This also includes evi-
dence suggesting that HSCs may be essential for hepatic
progenitor cell amplification and differentiation and be
involved in antigen presentation and induction of toler-
ance. Emerging evidence suggesting that hepatic MFs may
also originate from portal fibroblasts, the EMT process
and bone marrow-derived cells represent the major limi-
tation to these studies that theoretically may not represent
an absolute paradigm for all the fibrosis patterns.
Similarly, rodent models of CLD [1-6,13-22] including
those taking advantage of knock-out or transgenic mice,
have been instrumental in the mechanistic comprehen-
sion of major tissue, cellular and molecular mechanisms
relevant to liver fibrogenesis as well as in identifying
potential therapeutic targets. Although most of these
pathogenic features have been confirmed in clinical con-
ditions, major general limitations of animal models in
relation to human CLDs [15,23] are represented by the
fact that the most reliable rodent models of CLD usually
do not completely match either the histopathology or
selected pathophysiological features of the corresponding
human condition. For example [23], most common
rodent models of NASH lack the development of obesity
and insulin resistance (methionine and choline deficient
(MCD) diet) or significant progression towards fibrosis
(high fat diet). Moreover, when these models (chronic
CCl4 administration, bile duct ligation) are discontinued,
an almost complete reversion even from cirrhosis is
detected; a scenario that can hardly apply to human cir-
rhosis.
Hepatic MFs may originate following a common process of activation/transdifferentiation or by EMT, from the indicated cellular sourcesFigur  1
Hepatic MFs may originate following a common process of activation/transdifferentiation or by EMT, from the 
indicated cellular sources. Different roles, established or suggested, for hepatic MFs are also indicated.
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Recent data in the literature from clinical conditions and
experimental models [1-6,13-18] identify three major
mechanisms able to elicit and sustain liver fibrogenesis,
outlined below.
Chronic activation of the wound-healing reaction
As in other fibrogenic disorders affecting different organs
and systems, activation of the wound-healing reaction is
the most common and relevant mechanism in hepatic
fibrogenesis and is characterised by the following key fea-
tures: (a) persistence of parenchymal damage with varia-
ble degree of necrosis and apoptosis; (b) presence of a
heterogeneous inflammatory infiltrate including mono-
nuclear cells and cells of the immune system; (c) activa-
tion of different types of ECM-producing and MF-like cells
with marked proliferative, synthetic and contractile fea-
tures; and (d) qualitative and quantitative changes of
hepatic ECM, associated with limited or absent remodel-
ling in the presence of a persistent attempt of hepatic
regeneration [19].
Studies performed in the past two decades in animal mod-
els and human patients have outlined the role of several
growth factors and cytokines (released by activated
inflammatory cells, endothelial cells or by HSC and HSC/
MFs) involved in the chronic wound-healing reaction and
affecting the profibrogenic potential and phenotypic
responses of HSC/MFs, including PDGF, transforming
growth factor (TGF)β, connective tissue growth factor
(CTGF), endothelin 1 (ET1), monocyte chemoattractant
protein 1 (MCP1), and tumour necrosis factor (TNF)α [1-
6,13-19]. Accordingly, several signalling pathways, tran-
scription factors and related transcriptional gene regula-
tion have been dissected and identified as involved in the
process of activation of HSCs or in mediating phenotypic
responses of MFs.
Major emerging concepts in this area are the following: (a)
the role of adipokines and their possible involvement in
non-alcoholic fatty liver disease (NAFLD) and NASH, for
example, leptin, which is increased in obese patients with
NASH and in other patients with CLDs, has been linked to
fibrogenesis by experimental studies [20,21] and can
affect profibrogenic behaviour of HSC/MFs [22,23]; (b)
the role of hypoxia and angiogenesis that in CLDs have
been suggested to favour fibrogenic progression [24], with
HSC/MFs being able to both release proangiogenic
cytokines and respond to them [24,25]; (c) liver fibrosis
and, possibly, the initial stages of cirrhosis (unlikely for
advanced cirrhosis) are potentially reversible in the pres-
ence of effective therapy and/or aetiology eradication
[15,17], as regression of histopathology develops as a
result of increased apoptosis of HSC/MFs and MFs and is
paralleled by increased expression of interstitial colla-
genases by hepatic macrophages.
Oxidative stress and related reactive intermediates
Oxidative stress has been detected in all major clinical
conditions of CLDs and rodent experimental models, rep-
resenting the predominant profibrogenic mechanism in
NAFLD/NASH and ALD [18,23]. Increased generation of
reactive oxygen species (ROS) and other reactive interme-
diates and decreased efficiency of antioxidant defences
actively contributes to parenchymal cell death and to
excess tissue remodelling and fibrogenesis [1-
6,14,15,18,23]. ROS and other reactive mediators such as
4-hydroxynonenal (HNE) can be generated outside MFs
being released either by activated inflammatory cells or
hepatocytes damaged by the specific aetiological agent or
condition. ROS and HNE can affect the profibrogenic
response of MFs by modulating proliferation, synthesis of
ECM, migration and chemotaxis, as well as ECM remodel-
ling. Moreover, ROS generation within HSC/MFs has been
reported to occur in response to profibrogenics including
PDGF, angiotensin II and the adipokine leptin [26], being
equally able to positively modulate profibrogenic signal-
ling pathways through involvement of nicotinamide ade-
nine dinucleotide phosphate (NADPH) oxidase [18,26],
including ROS generation following phagocytosis of
apoptotic bodies from damaged hepatocytes by HSC/MFs
[27].
A final concept to mention is that the immune response
triggered by oxidative stress may have a significant role in
the progression of ALD, in the worsening of chronic hep-
atitis C by alcohol intake and, possibly, even in the pro-
gression of NAFLD [28].
Derangement of epithelial-mesenchymal interactions and 
epithelial-mesenchymal transition in cholangiopathies
Cholangiopathies in adult and paediatric patients are
characterised by cholestasis, necrotic or apoptotic loss of
cholangiocytes, cholangiocyte proliferation (that is, duc-
tular reaction) as well as portal/periportal inflammation
and fibrosis. Intense proliferation of cholangiocytes is
associated with recruitment of portal fibroblasts and
HSCs followed by parenchyma invasion and biliary fibro-
sis. This scenario is dominated by an intense crosstalk
between mesenchymal cells and cholangiocytes, the latter
able to secrete chemokines (interleukin (IL)6, TNFα, IL8,
MCP1) and profibrogenic factors (PDGF-BB, ET1, CTGF,
TGFβ2) [2], and, as recently proposed, by a process of 'epi-
thelial to mesenchymal transition' involving cholangi-
ocytes and possibly driven by TGFβ [3,4,12].
Take-home messages
Basic science advances
Liver fibrogenesis is sustained by a heterogeneous popula-
tion of profibrogenic hepatic MFs, the majority being pos-
itive for αSMA that may originate from different cellular
sources including hepatic stellate cells and portal fibrob-
lasts following a process of activation, bone marrowPage 4 of 6
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troversial method, by a process of EMT involving cholan-
giocytes and hepatocytes.
Present knowledge on hepatic MFs is derived mainly from
studies performed on activation of HSC in CLDs, that
progress in sequential stages of initiation and perpetua-
tion. Initiation is an early response stimulated by para-
crine signals leading to a transient, potentially reversible,
contractile and profibrogenic phenotype, characterised by
rapid induction of PDGFβ receptor and primed to
respond to growth factors and mediators crucial in elicit-
ing phenotypic responses operated by fully activated MF-
like phenotypes (perpetuation), including proliferation,
migration/chemotaxis, contractility, excess deposition
and altered remodelling of the ECM.
Recent data in the literature from clinical conditions and
experimental models have identified, at the tissue, cellular
and molecular level, three major mechanisms able to
elicit and sustain liver fibrogenesis: (a) chronic activation
of the wound-healing reaction, (b) oxidative stress and
related reactive intermediates, and (c) derangement of
epithelial-mesenchymal interactions.
Clinical science advances
The elucidation of the cellular and molecular mechanisms
regulating fibrogenesis in chronic liver disease have pro-
vided relevant clinical advances in the identification of
diagnostic and therapeutic strategies.
Several biomarkers, related to the biology of fibrogenesis
are currently validated for their use as diagnostic and
prognostic indicators of disease progression in different
chronic liver diseases. Some of these markers are likely to
replace or integrate the use of repeated liver biopsies in
the follow-up of patients undergoing treatment. In addi-
tion, several potentially effective antifibrotic compounds
have been identified, as previously detailed [2], and are
awaiting clinical testing in large clinical trials.
Relevance to clinical care
In the past decade, practicing hepatologists have finally
directed their attention to hepatic fibrosis and its clinical
implications, including the possibility of regression
obtained by specific therapeutic interventions. Therefore,
the issue of 'fibrosis regression' represents a current hot
topic.
Since the degree of fibrosis in a non-cirrhotic liver is
devoid of corresponding clinical manifestations, the main
endpoint should be downstaging or, at least, stabilising
fibrosis (that is, inducing a lack of progression). In other
words, adequate therapy might ensure that the patient
will die of other causes 'with' liver fibrosis rather than
dying 'of' cirrhosis.
In cirrhotic patients, the reduction of fibrosis within cir-
rhotic liver tissue would lead to a reduction of portal
hypertension and of the consequent clinical complica-
tions and to an overall improvement of liver function,
thus extending the complication-free patient survival time
and reducing the need for liver transplantation.
Caution, critical remarks and recommendations
Although the relevant advances in basic knowledge on
fibrosis obtained in the last 20 years have greatly pro-
moted clinical applications pivotal for patient manage-
ment, caution should be applied when translating basic
concepts into clinical practice. Indeed, the search for effec-
tive antifibrogenic strategies is based on the knowledge
gained in in vitro experiments and in experiments employ-
ing animal models of liver fibrosis. Besides the obvious
consideration that in vitro data do not fully capture the sit-
uation in the whole organ and organism, it is also clear
that none of the available animal model faithfully reflects
human liver disease. Therefore, definite conclusions can
be drawn only by clinical trials performed in humans.
In addition, while it is clear that the introduction of anti-
fibrotic agents would represent a great therapeutic advan-
tage, it is also absolutely clear that the best antifibrogenic
treatment would be any strategy able to eliminate the pri-
mary cause of parenchymal damage, metabolic overload
or excessive oxidative stress. Since the fibrogenic process is
in essence a compensatory phenomenon aimed at main-
taining a sufficient tissue continuity and cohesion in the
presence of a continuous microscopic parenchymal col-
lapse, it would be erroneous to attempt to cure fibrogenic
CLDs only with antifibrogenic drugs.
Future developments
A large effort is currently directed at identifying gene pol-
ymorphisms conditioning the rate of fibrosis progression
in CLDs. The applications of 'omics' platforms (genomics,
proteomics, metabolomics, and so on) has already gener-
ated an enormous amount of data that now needs to be
analysed, framed in the clinical features of the disease and
validated in larger cohorts. It is still unclear how these
findings will translate to application with clinical utility in
everyday practice. Regardless, molecular markers of the
progression of fibrosis could help define new end points
during antiviral therapy. Therefore, gene changes could be
new markers of the progression of fibrosis during antiviral
treatment. In addition, many of the upregulated genes
identified in gene expression studies would represent
potential molecular targets for the development of antifi-
brotic drugs.Page 5 of 6
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